Ovid Therapeutics Inc. · NASDAQ:OVID

Ovid Therapeutics — 2022 Epilepsy Foundation Pipeline Conference

9 slides from Ovid Therapeutics's conference presentation, Jun 5, 2022

  1. Slide 1: Preclinical Data Supporting the Efficacy of OV329, A Next-Generation GABA Aminotransferase Inhibitor, Against Seizures

    Preclinical Data Supporting the Efficacy of OV329, A Next-Generation GABA Aminotransferase Inhibitor, Against Seizures Julia Tsai, Ph.D. Ovid Therapeutics 2022 Epilepsy Foundation Pipeline Conference 1 ©2020 Epilepsy Foundation of America, Inc.

  2. Slide 2: Disclaimers & forward-looking statements

    Disclaimers & forward-looking statements This presentation includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the timing and development of Ovid’s product candidate pipeline, including the timing for filing of an IND for OV329

  3. Slide 3: Ovid Therapeutics

    Ovid Therapeutics Vision: Conquer epilepsies & brain disorders with courageous science • 3 preclinical programs with potential 1st-in-class or best-in- class medicines • Novel mechanisms of action for the potential treatment of epilepsy • Out-licensed novel cholesterol 24-hydroxylase inhibitor to Ta

  4. Slide 4: OV329 is a potent, next-generation GABA-AT inhibitor

    OV329 is a potent, next-generation GABA-AT inhibitor OV329 facilitates GABA transmission • Potential candidate for treatment of Vigabatrin OV329 Presynaptic Neuron = GABA drug-resistant epilepsy GAT = GABA Glutamine transporter • Well-characterized target Glial Cell Glutamate • Similar mechanism of

  5. Slide 5: OV329 is active in suppressing seizures in multiple animal models, including drug-resistant models

    OV329 is active in suppressing seizures in multiple animal models, including drug-resistant models PRESENTED TODAY Intrahippocampal Kainate Model of Maximal i.v. NMDA-Induced Mesial-Temporal 6 Hz Electrical Electroshock Pentylenetetrazol Infantile Spasm Audiogenic Amygdala Corneal Lobe Epilepsy Stim

  6. Slide 6: OV329 significantly reduces seizures in the Corneal Kindled mouse

    OV329 significantly reduces seizures in the Corneal Kindled mouse Dose response at 8 hours Seizure protection in fully kindled mice *P<0.05, ***P<0.001 - one-way ANOVA, Dunnett’s post-hoc test ED50a 95% Confidence Interval pb zc UU 27.92 (19 – 36.7) *P<0.05, **P<0.01, Fisher’s exact test (vs. VEH) C

  7. Slide 7: OV329 significantly reduces seizures in the Mesial-Temporal Lobe Epilepsy (MTLE) mouse model

    OV329 significantly reduces seizures in the Mesial- Temporal Lobe Epilepsy (MTLE) mouse model Single administration of OV329 reduced the number Repeat dosing of OV329 demonstrates activity in the MTLE of hippocampal paroxysmal discharges (HPDs)1 mouse model of drug-resistant epilepsy at low doses Ve

  8. Slide 8: OV329 preclinical efficacy & safety data support moving toward IND

    OV329 preclinical efficacy & safety data support moving toward IND OV329, a next-generation GABA-AT inhibitor, is in development as an anti-seizure medication for rare adult and pediatric epilepsy disorders Planning IND submission Non-clinical studies have demonstrated anti-seizure activity of OV329

  9. Slide 9: Thank you to the families who help make this work possible.

    Thank you to the families who help make this work possible.

Ovid Therapeutics — 2022 Epilepsy Foundation Pipeline Conference on 6ix